Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific... – Virus
Reexamination Certificate
1996-08-20
2004-10-19
Wortman, Donna C. (Department: 1648)
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
Virus
C424S093600, C424S232100, C435S236000, C435S238000
Reexamination Certificate
active
06805870
ABSTRACT:
This invention relates to multipotent paramunity inducers based on combinations of poxvirus components, a method for preparing same, and their use as drugs.
The immune system of warm-blooded animals, especially of mammals and birds, consists of an antigen-specific part and an antigen non-specific part. The two parts are cross-linked and so form a uniform organic system. The antigen-specific mechanisms are responsible for building up an immunity, while the antigen non-specific are responsible for building up paramunity. Accordingly, for both historical and functional reasons the antigen non-specific part of the defence is known as the paraspecific immune system. Up until the present, immunology research has been mainly concerned with the antigen-specific part of the immune system, i.e. with how immunity is formed. The utilization of this defence potential led for example to the development of active and passive immunization. In contrast, the exploitation of the paraspecific activities of the immune system for prevention and cure is still in its early stages. The paraspecific immune system makes it possible for the organism to mount an immediate defence when confronted by the most diverse foreign substances, infectious pathogens, toxins and transformed cells of the organism itself. There are patterns of close functional interplay between the paraspecific and the specific activities of the immune system, generally involving a flow of information from the paraspecific mechanisms, which react first, to the specific mechanisms of the immune system. In this way, in cases where there is infection with particularly virulent pathogens the paraspecific defence of the organism is able to bridge the gap until specific immunity has had time to develop.
Since Edward Jenner introduced protective immunization against smallpox in 1798 using a vaccine obtained from animals (cattle or horses) and based on the vaccinia virus, empirically obtained results have been reported showing that protective immunization against smallpox resulted in those vaccinated recovering surprisingly rapidly, or without complications, from other infections and diseases, especially chronic and relapsing complaints, from which they happened to be suffering at the time of vaccination. In particular this applies to herpes infections of varying genesis, papillomas, chronic eczemas and pathological conditions of the ears, nose and throat. As well as this, however, it was noted that those immunized showed a generally raised short-term level of resistance to acute ambient infections. Similar phenomena have been noted after protective immunization against forms of animal pox. It was deduced from these findings that poxviruses or certain structural components of these viruses can positively influence the organism's ability to resist infections and tumours, on a non-specific level. Because these non-specific healing processes commence immediately after vaccination and hence 5 to 7 days before the specific immunity conferred by vaccination develops, as well as parallel thereto, in 1978 A. Mayr designated these non-specific consequences of a prophylactic immunization as “paraspecific”. Accordingly, medicaments produced specifically to exploit such paraspecific effects are known as “paramunity inducers”; see A. Mayr, ‘Prämunität, Prämunisierung und paraspezifische Wirkung von Schutzimpfungen’, Münch. Med. Wschr. 1978, Vol. 120, pp. 239 to 242; A. Mayr, H. Raettig, H. Stickl and M. Alexander, 1979: ‘Paramunität, Paramunisierung, Paramunitätsinducer’, Fortschr. Med. 97, pp. 1159 to 1165 and 1205 to 1210.
DE-A-27 14 665 and U.S. Pat. No. 4,191,745 disclose preparations based on poxviruses for treating herpes zoster and other herpes infections. In veterinary medicine, paramunity inducers have been produced from purified, attenuated and inactivated avipox and parapox viruses. These paramunity inducers are registered in the European countries as “Duphapind
R
” and “Duphamun
R
” (PIND-AVI) and as “Baypamun
R
” (PIND-ORF) for virtually all species of farm and domestic animals. Paramunity inducer PIND-AVI is prepared from an attenuated avipox virus, strain HP-1, and paramunity inducer PIND-ORF is prepared from an attenuated parapox virus, strain D-1701. The attenuated viruses are rendered inactive in a manner known per se, e.g. by &ggr;-radiation or chemical means such as treatment with &bgr;-propiolactone.
The drugs with paramunizing properties which are preferred for use as immunostimulants and to provide “adjuvant immunotherapy” in human medicine are BCG (Bacillus Calmette Guerin), levamisole and
Corynebacterium parvum
(syn.
Propionibacterium acnes
). However, these preparations are inferior to the poxvirus-based paramunity inducers in terms of their paramunizing action, as may be seen from the results summarized in Table 1, which were obtained in tests in which these preparations were compared with PIND-AVI and PIND-ORF in the VSV baby mouse test; see A. Mayr, A. M. Büttner, S. Pawlas, V. Erfle, B. Mayr, R. Brunner and K. Osterkorn, 1986: ‘Vergleichende Untersuchungen über die immunstimulierende (paramunisierende) Wirksamkeit von BCG, Levamisol,
Corynebacterium parvum
und Präparaten aus Pockenviren in verschiedenen “in vivo”—und “in vitro”—Testen’, J. Vet. Med. B 33, pp. 321 to 339.
It is the object of the present invention to provide, for therapeutic applications in human and veterinary medicine, multipotent paramunity inducers based on poxvirus components, which have been improved in respect of their potency and in respect of their paramunization-related activities. It is a further object of the present invention to provide an improved method for preparing said multipotent paramunity inducers using a new technique of virus propagation in cell cultures and/or virus inactivation. Lastly, it is yet another object of the invention to provide pharmaceutical compositions for use as drugs based on said multipotent paramunity inducers.
The invention therefore relates to multipotent paramunity inducers based on a combination of two or more poxvirus components derived from various poxvirus strains having paramunizing properties. The invention further relates to multipotent paramunity inducers based on a combination of a plurality of different species of inactivated, attenuated poxviruses with paramunizing properties. The invention also relates to a method for preparing paramunity inducers in which two or more poxvirus components derived from different poxvirus strains with paramunizing properties are combined. Lastly, the invention relates to methods for preparing the multipotent paramunity inducers according to the invention, and to pharmaceutical compositions comprising said multipotent paramunity inducers, for use as drugs.
It was unexpectedly found that combining poxvirus components in the multipotent paramunity inducers according to the invention does not result in a decrease in, let alone loss of, the respective paramunizing activities of the individual poxvirus components. Instead it was seen that combining the poxvirus components derived from various poxvirus strains in the multipotent paramunity inducers according to the invention brings about not only an additive or supplementary effect, but a potentiation of the respective paramunizing action. Experiments have shown that the action of the multipotent paramunity inducers combined from poxvirus components far exceeds their respective individual actions. This phenomenon could not have been predicted, and in terms of their potency and their paramunisation-related activities it enhances these paramunity inducers as compared with conventional preparations from a single poxvirus component. Another unexpected finding is that the multipotent paramunity inducers according to the invention have virtually no immunogenic properties, but do have very strong paramunizing properties, as a result of which they can safely be administered on a repeated or continuous basis.
The invention is also based on the unexpected finding that a competitive situation exists between the epitopes of the stru
Barnes & Thornburg
Martin Alice O.
Wortman Donna C.
LandOfFree
Paramunity inducer based on combinations of poxvirus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Paramunity inducer based on combinations of poxvirus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Paramunity inducer based on combinations of poxvirus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3283408